Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019October 10, 2019 Alterity Therapeutics

Alterity PBT434 Poster – MDS 2019 Congress

Post navigation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Quarterly Cash Flow Report

Related Posts

Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track

July 17, 2013

Prana’s Founding Scientist and CSA publishes landmark paper in Nature

October 12, 2014

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

July 3, 2017

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

XBRL 30 June 2020 filed with the SEC
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065